Drug Profile
Mesothelin CAR-T cell therapy - Shenzhen BinDeBio
Alternative Names: CART-meso cells - Shenzhen BinDeBioLatest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Shenzhen BinDeBio
- Developer Henan Provincial Hospital; Jiangsu Provincial Peoples Hospital; Shenzhen BinDeBio
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Gastric cancer
- No development reported Pancreatic cancer
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for clinical-Phase-Unknown development in Pancreatic-cancer(In the elderly, In adults) in China (IV, Infusion)
- 15 May 2019 Phase-I/II clinical trials in Gastric cancer (Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable) in China (IV) (NCT03941626)
- 11 Jul 2018 Clinical trials in Pancreatic cancer (In adults, In the elderly) in China (IV) (NCT03638193)